Immunocore Holdings plc - ADR Stock News

Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robertson - Head of Investor Relations David Berman - Executive Vice President of Research Development Mohammed M. Dar - Senior VP of Clinical Development & Chief Medical Officer Ralph Torbay - Corporate...

Immunocore Plc (IMCR 0.06%), a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increase, with $98.0 million (GAAP) surpassing consensus estimates of $92.15 million.

KIMMTRAK ® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by Immunocore (Nasdaq: IMCR) as the distribution and commercialization partner for KIMMTRAK, for the treatment of HLA-A*02:01-positive adults wi...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate pre...

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.